MX2009007502A - Derivados de espirocromanona sustituidos. - Google Patents
Derivados de espirocromanona sustituidos.Info
- Publication number
- MX2009007502A MX2009007502A MX2009007502A MX2009007502A MX2009007502A MX 2009007502 A MX2009007502 A MX 2009007502A MX 2009007502 A MX2009007502 A MX 2009007502A MX 2009007502 A MX2009007502 A MX 2009007502A MX 2009007502 A MX2009007502 A MX 2009007502A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- cyclo
- alkyl
- substituted
- alkoxy
- Prior art date
Links
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical class 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000006828 (C2-C7) alkoxycarbonyl group Chemical group 0.000 abstract 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 abstract 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 abstract 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 abstract 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 1
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine Chemical compound C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 abstract 1
- FKWUPVHNVKGGSD-UHFFFAOYSA-N 1h-thieno[2,3-c]pyrazole Chemical compound C1=NNC2=C1C=CS2 FKWUPVHNVKGGSD-UHFFFAOYSA-N 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
Abstract
La invención se refiere a un compuesto de fórmula general (I): (ver fórmula (I)) en la que Ar1 representa un grupo formado desde un anillo aromático seleccionado del grupo constituido por indol, 1H-indazol, 2H-indazol, 1H-tieno[2,3-c]pirazol, 1H-pirazolo[3,4-b]piridina, benzo[b]furano, bencimidazol, benzoxazol, 1,2-bencisoxazol e imidazo[1,2-a]piridina; R1 y R2 representan cada uno un átomo de hidrógeno, un átomo de halógeno, un grupo ciano, un grupo alquenilo C2-C6, un grupo alcoxi C1-C6, un grupo haloalcoxi C1-C6, un grupo cicloalquiloxi C3-C6, un grupo alcanoílo C2-C7, un grupo haloalcanoílo C2-C7, un grupo alcoxicarbonilo C2-C7, un grupo haloalcoxicarbonilo C2-C7, un grupo cicloalcoxicarbonilo C3-C6, un grupo aralquiloxicarbonilo, un grupo carbamoilalcoxi C1-C6, un grupo carboxialquenilo C2-C6, o un grupo de -Q1-N(Ra)-Q2-Rb; un grupo alquilo C1-C6, arilo o heterocíclico opcionalmente sustituido; o un grupo alquilo C1-C6, o alquenilo C2-C6 que tienen el grupo arilo o heterocíclico; R3 y R4 representan cada uno un átomo de hidrógeno, un átomo de halógeno, un grupo nitro, un grupo cicloalquilo C3-C6, un grupo carbamoílo opcionalmente sustituido por un grupo alquilo C1-C6 o un grupo cicloalquilo C3-C6 o un grupo de -N(Re)Rf; un grupo alcanoílo C2-C7, alcoxi C1-C6 alcoxicarbonilo C2-C7, cicloalcoxicarbonilo C3-C6, alquilsulfonilo C1-C6, alquiltio C1-C6 cicloalquiloxi C3-C6, cicloalquil C3-C6-alcoxi C1-C6, cicloalquilsulfonilo C3-C6, cicloalquiltio C3-C6 o cicloalquil C3-C6-alquiltio C1-C6 opcionalmente sustituido; o un grupo alquilo C1-C6 opcionalmente sustituido; T y U representan cada uno un átomo de nitrógeno o un grupo metino; y V representa un átomo de oxígeno o un átomo de azufre; el compuesto de la invención es útil como agente terapéutico para diversas enfermedades relacionadas con la ACC.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88030207P | 2007-01-12 | 2007-01-12 | |
| PCT/US2008/000221 WO2008088688A1 (en) | 2007-01-12 | 2008-01-08 | Substituted spirochromanone derivatives as acc inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009007502A true MX2009007502A (es) | 2009-07-17 |
Family
ID=39297859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009007502A MX2009007502A (es) | 2007-01-12 | 2008-01-08 | Derivados de espirocromanona sustituidos. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8093389B2 (es) |
| EP (1) | EP2111406B1 (es) |
| JP (1) | JP5319550B2 (es) |
| KR (1) | KR20090108022A (es) |
| CN (1) | CN101631791B (es) |
| AR (1) | AR064824A1 (es) |
| AU (1) | AU2008205638B2 (es) |
| BR (1) | BRPI0806531A2 (es) |
| CA (1) | CA2674573C (es) |
| CL (1) | CL2008000067A1 (es) |
| CO (1) | CO6190611A2 (es) |
| CR (1) | CR10944A (es) |
| DO (1) | DOP2009000176A (es) |
| EC (1) | ECSP099503A (es) |
| GT (1) | GT200900194A (es) |
| HN (1) | HN2009001276A (es) |
| MA (1) | MA31108B1 (es) |
| MX (1) | MX2009007502A (es) |
| NI (1) | NI200900139A (es) |
| NZ (1) | NZ577825A (es) |
| PE (1) | PE20081559A1 (es) |
| RU (1) | RU2009130736A (es) |
| SG (1) | SG177977A1 (es) |
| TW (1) | TW200836727A (es) |
| UA (1) | UA103990C2 (es) |
| WO (2) | WO2008088688A1 (es) |
| ZA (1) | ZA200904138B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2614963C (en) * | 2005-07-19 | 2014-10-07 | Merck & Co., Inc. | Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors |
| AU2008205642B2 (en) * | 2007-01-12 | 2013-06-06 | Msd K.K. | Spirochromanon derivatives |
| US7946800B2 (en) | 2007-04-06 | 2011-05-24 | Brooks Automation, Inc. | Substrate transport apparatus with multiple independently movable articulated arms |
| US8752449B2 (en) | 2007-05-08 | 2014-06-17 | Brooks Automation, Inc. | Substrate transport apparatus with multiple movable arms utilizing a mechanical switch mechanism |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CA2724774C (en) | 2008-05-28 | 2013-06-25 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| WO2010002010A1 (en) * | 2008-07-04 | 2010-01-07 | Banyu Pharmaceutical Co.,Ltd. | Novel spirochromanone carboxylic acids |
| CA2730493A1 (en) * | 2008-07-14 | 2010-01-21 | Cropsolution, Inc. | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
| SG171765A1 (en) | 2008-11-20 | 2011-07-28 | Genentech Inc | Pyrazolopyridine pi3k inhibitor compounds and methods of use |
| NZ599815A (en) * | 2009-11-10 | 2013-04-26 | Pfizer | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CA3017128C (en) * | 2009-12-31 | 2021-08-31 | Deka Products Limited Partnership | Infusion pump assembly |
| WO2011140425A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| CN101851237B (zh) * | 2010-06-18 | 2012-10-17 | 南方医科大学 | 一种螺环化合物及其制备方法和应用 |
| JP5824055B2 (ja) | 2010-09-30 | 2015-11-25 | ファイザー・インク | Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害剤 |
| HUE025078T2 (en) | 2010-10-29 | 2016-01-28 | Pfizer | N1 / N2-lactam-acetyl-CoA carboxylase inhibitors |
| WO2012077655A1 (ja) * | 2010-12-07 | 2012-06-14 | 塩野義製薬株式会社 | Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体 |
| AR085893A1 (es) | 2011-02-02 | 2013-11-06 | Vertex Pharma | Pirrolopirazina-amidas de piperidina espirociclica como moduladores de los canales ionicos |
| CA2827311A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| MX348860B (es) | 2011-04-22 | 2017-06-30 | Pfizer | Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa. |
| WO2012161119A1 (ja) * | 2011-05-20 | 2012-11-29 | 興和株式会社 | 新規なスピロピペリジン誘導体及びこれを含有する医薬 |
| WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113720A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| IN2014DN07224A (es) | 2012-02-03 | 2015-04-24 | Basf Se | |
| AR089884A1 (es) | 2012-02-03 | 2014-09-24 | Basf Se | Compuestos fungicidas de pirimidina |
| WO2013113787A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| MX2015015422A (es) | 2013-05-10 | 2016-06-21 | Nimbus Apollo Inc | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. |
| EP2994141A4 (en) | 2013-05-10 | 2016-11-23 | Nimbus Apollo Inc | ACC-HEMMER AND USES THEREOF |
| WO2015036892A1 (en) | 2013-09-12 | 2015-03-19 | Pfizer Inc. | Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris |
| WO2018112204A1 (en) | 2016-12-14 | 2018-06-21 | Cephalon, Inc. | Spiropiperidine derivatives |
| AU2018291163B2 (en) * | 2017-06-30 | 2024-07-18 | Quixgen, Inc. | Novel spirolactone compounds |
| CN120019059A (zh) * | 2022-07-29 | 2025-05-16 | 辉瑞公司 | 新型acc抑制剂 |
| CN119798270A (zh) * | 2025-01-06 | 2025-04-11 | 中国海洋大学 | 靶向egfr的小分子化合物及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2814983A1 (de) | 1978-04-07 | 1979-10-18 | Bayer Ag | Neue chromanon-derivate |
| JPH03182725A (ja) | 1989-12-08 | 1991-08-08 | Internatl Business Mach Corp <Ibm> | 非線形光学素子及びその製造方法 |
| US5206240A (en) | 1989-12-08 | 1993-04-27 | Merck & Co., Inc. | Nitrogen-containing spirocycles |
| IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| WO1994017045A1 (en) | 1993-01-28 | 1994-08-04 | Merck & Co., Inc. | Spiro-substituted azacycles as tachykinin receptor antagonists |
| CA2189634A1 (en) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Combinatorial dihydrobenzopyran library |
| US5688997A (en) | 1994-05-06 | 1997-11-18 | Pharmacopeia, Inc. | Process for preparing intermediates for a combinatorial dihydrobenzopyran library |
| US5856083A (en) | 1994-05-06 | 1999-01-05 | Pharmacopeia, Inc. | Lawn assay for compounds that affect enzyme activity or bind to target molecules |
| US6017768A (en) | 1994-05-06 | 2000-01-25 | Pharmacopeia, Inc. | Combinatorial dihydrobenzopyran library |
| EP0831824A4 (en) | 1995-06-06 | 2001-05-02 | Merck & Co Inc | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
| GB9601724D0 (en) | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
| GB0003397D0 (en) | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2002020509A2 (de) | 2000-09-06 | 2002-03-14 | Bayer Aktiengesellschaft | Arzneimittel gegen virale erkrankungen |
| JP2005170790A (ja) | 2002-01-09 | 2005-06-30 | Ajinomoto Co Inc | Ｎ−アルキルスルフォニル置換アミド誘導体 |
| JP2005162612A (ja) | 2002-01-09 | 2005-06-23 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| PL372887A1 (en) | 2002-02-27 | 2005-08-08 | Pfizer Products Inc. | Acc inhibitors |
| JP2005320250A (ja) | 2002-05-09 | 2005-11-17 | Ajinomoto Co Inc | ビスラクトン誘導体及びその医薬組成物としての使用 |
| AU2003299791A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
| WO2004092179A1 (ja) * | 2003-04-14 | 2004-10-28 | Nippon Soda Co. Ltd. | スピロ誘導体、製造法および抗酸化薬 |
| FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2005119987A (ja) * | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| WO2006040329A1 (en) * | 2004-10-12 | 2006-04-20 | Novo Nordisk A/S | 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds |
| KR20070097441A (ko) | 2004-11-18 | 2007-10-04 | 인사이트 산 디에고 인코포레이티드 | 11-β 하이드록실 스테로이드 데하이드로게나제 유형 1의억제제 및 이를 사용하는 방법 |
| CA2605985A1 (en) * | 2005-05-03 | 2006-11-09 | Pfizer Inc. | Amide resorcinol compounds |
| CA2614963C (en) * | 2005-07-19 | 2014-10-07 | Merck & Co., Inc. | Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors |
| CA2670422C (en) * | 2006-11-29 | 2011-09-06 | Pfizer Products Inc. | Spiroketone acetyl-coa carboxylase inhibitors |
| AU2008205642B2 (en) * | 2007-01-12 | 2013-06-06 | Msd K.K. | Spirochromanon derivatives |
-
2008
- 2008-01-04 PE PE2008000089A patent/PE20081559A1/es not_active Application Discontinuation
- 2008-01-07 TW TW097100608A patent/TW200836727A/zh unknown
- 2008-01-08 JP JP2009545577A patent/JP5319550B2/ja not_active Expired - Fee Related
- 2008-01-08 CN CN2008800021443A patent/CN101631791B/zh not_active Expired - Fee Related
- 2008-01-08 WO PCT/US2008/000221 patent/WO2008088688A1/en not_active Ceased
- 2008-01-08 CA CA2674573A patent/CA2674573C/en not_active Expired - Fee Related
- 2008-01-08 EP EP08713050A patent/EP2111406B1/en active Active
- 2008-01-08 UA UAA200908468A patent/UA103990C2/ru unknown
- 2008-01-08 NZ NZ577825A patent/NZ577825A/en not_active IP Right Cessation
- 2008-01-08 AU AU2008205638A patent/AU2008205638B2/en not_active Ceased
- 2008-01-08 MX MX2009007502A patent/MX2009007502A/es unknown
- 2008-01-08 KR KR1020097014377A patent/KR20090108022A/ko not_active Withdrawn
- 2008-01-08 SG SG2012002739A patent/SG177977A1/en unknown
- 2008-01-08 US US12/007,000 patent/US8093389B2/en active Active
- 2008-01-08 RU RU2009130736/04A patent/RU2009130736A/ru not_active Application Discontinuation
- 2008-01-08 WO PCT/US2008/000223 patent/WO2008088689A1/en not_active Ceased
- 2008-01-08 BR BRPI0806531-4A2A patent/BRPI0806531A2/pt not_active IP Right Cessation
- 2008-01-09 AR ARP080100081A patent/AR064824A1/es not_active Application Discontinuation
- 2008-01-10 CL CL200800067A patent/CL2008000067A1/es unknown
-
2009
- 2009-06-12 ZA ZA200904138A patent/ZA200904138B/xx unknown
- 2009-07-06 HN HN2009001276A patent/HN2009001276A/es unknown
- 2009-07-06 GT GT200900194A patent/GT200900194A/es unknown
- 2009-07-08 NI NI200900139A patent/NI200900139A/es unknown
- 2009-07-09 EC EC2009009503A patent/ECSP099503A/es unknown
- 2009-07-09 DO DO2009000176A patent/DOP2009000176A/es unknown
- 2009-07-13 CO CO09072490A patent/CO6190611A2/es active IP Right Grant
- 2009-07-20 CR CR10944A patent/CR10944A/es unknown
- 2009-07-23 MA MA32114A patent/MA31108B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009007502A (es) | Derivados de espirocromanona sustituidos. | |
| WO2008088692A3 (en) | Spirochromanon derivatives | |
| MA31109B1 (fr) | Nouveaux derives d'aminopyrimidine servant d'inhibiteurs de la plk1. | |
| AU2009298008B2 (en) | Pyrazolo pyridine derivatives as NADPH Oxidase inhibitors | |
| IL185844A0 (en) | I-acetic acid-indole derivatives with pgd2 antagonist activity | |
| WO2008145839A8 (fr) | Dérivés de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur préparation et leur application en thérapeutique | |
| PE20040832A1 (es) | Derivados de indolil pirazinona | |
| MY139887A (en) | Tetrahydronaphthyridine derivatives and a process for preparing the same. | |
| WO2009144394A8 (fr) | Derives de 2-aryl-6-phenyl-imidazo[1,2-a]pyridines polysubstitues, leur préparation et leur application en thérapeutique | |
| WO2003024967A3 (en) | Indolizines as kinase protein inhibitors | |
| NZ591712A (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| AR031345A1 (es) | Derivados de benzodiazepina como moduladores receptores gaba a | |
| IN2012DN00770A (es) | ||
| Sheng et al. | Metal-free synthesis of imidazo [1, 5-a] pyridines via elemental sulfur mediated sequential dual oxidative Csp 3–H amination | |
| PE20090280A1 (es) | Pirazol-pirrolidinas como inhibidores de gamma secretasa | |
| CA2398988A1 (en) | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | |
| PE20100737A1 (es) | Nuevos compuestos | |
| TW200732338A (en) | Aromatic compound | |
| WO2001058896A8 (en) | Benzoxazole derivatives as tnf and pde iv inhibitors | |
| ATE337827T1 (de) | N-aryl-4,5-diaminopyrazole und diese verbindungen enthaltende färbemittel | |
| DK1381370T3 (da) | N-Biphenylcarbonyl- og N-phenylpyridylcarbonyl-substituerede bi- og tricykliske azepiner og diazepiner som vasopressin-agonister | |
| MXPA05014191A (es) | Procedimiento para preparar derivado de acido 3-acilaminobenzofuran-2-carboxilico. | |
| Sirakanyan et al. | New Methods for the Synthesis of 3‐Amino‐6, 7‐Dihydro‐5H‐Cyclopenta [c] Pyridine‐4‐Carbonitriles and Cyclopenta [d] Pyrazolo [3, 4‐b] Pyridines via a Smiles‐type Rearrangement | |
| ATE524471T1 (de) | Pyrazolonaphthyridinderivat | |
| Khidre et al. | Synthesis and Antimicrobial Activity of Novel Heterocycles Utilizing 3‐(1, 4‐Dioxo‐3, 4‐dihydrophthalazin‐2 (1 H)‐yl)‐3‐oxopropanenitrile as Precursors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: MICROSOFT TECHNOLOGY LICENSING, LLC |